-+ 0.00%
-+ 0.00%
-+ 0.00%

PDS Biotech Adds PFS Interim Primary Endpoint to Phase 3 VERSATILE-003 Trial for PDS0101 in HPV16-Positive Head and Neck Cancer

Reuters·02/20/2026 13:30:29

Please log in to view news